NRIX Nurix Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NRIX

Price (delayed)

$15.33

Market cap

$1.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.17

Enterprise value

$1.57B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 67
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 26

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer ...

Highlights
The revenue has grown by 27% YoY but it has contracted by 15% from the previous quarter
NRIX's gross profit is up by 27% YoY but it is down by 15% from the previous quarter
NRIX's debt has surged by 120% year-on-year and by 5% since the previous quarter
The net income has declined by 42% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nurixtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of NRIX

NRIX stock price

How has the Nurix Therapeutics stock price performed over time
Intraday
-0.97%
1 week
-13.24%
1 month
-9.45%
1 year
26.07%
YTD
-19.19%
QTD
-1.1%

Financial performance

How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$71.78M
Gross profit
$71.78M
Operating income
-$315.3M
Net income
-$295.28M
Gross margin
100%
Net margin
-411.4%
The net income has declined by 42% year-on-year and by 12% since the previous quarter
The operating income has declined by 37% year-on-year and by 10% since the previous quarter
NRIX's net margin is down by 31% since the previous quarter and by 11% year-on-year
Nurix Therapeutics's operating margin has decreased by 29% QoQ and by 7% YoY

Price vs fundamentals

How does NRIX's price correlate with its fundamentals

Growth

What is Nurix Therapeutics's growth rate over time

Valuation

What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
3.28
P/S
23.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.9
NRIX's EPS is down by 13% year-on-year and by 3.9% since the previous quarter
The stock's price to book (P/B) is 38% more than its last 4 quarters average of 2.4 and 32% more than its 5-year quarterly average of 2.5
NRIX's equity is down by 11% since the previous quarter
The stock's price to sales (P/S) is 52% more than its last 4 quarters average of 15.6 and 25% more than its 5-year quarterly average of 19.0
The revenue has grown by 27% YoY but it has contracted by 15% from the previous quarter

Efficiency

How efficient is Nurix Therapeutics business performance
The ROE has contracted by 35% YoY and by 12% from the previous quarter
NRIX's return on assets is down by 34% year-on-year and by 11% since the previous quarter
NRIX's return on sales is down by 31% since the previous quarter and by 11% year-on-year
NRIX's return on invested capital is down by 28% year-on-year and by 8% since the previous quarter

Dividends

What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRIX.

Financial health

How did Nurix Therapeutics financials performed over time
Nurix Therapeutics's total liabilities has increased by 16% YoY and by 3.9% QoQ
NRIX's quick ratio is down by 14% since the previous quarter and by 3.9% year-on-year
NRIX's debt is 88% smaller than its equity
NRIX's debt has surged by 120% year-on-year and by 5% since the previous quarter
The debt to equity has surged by 100% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.